Journal: Arthritis Research & Therapy

Article Title: A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients

doi: 10.1186/ar2002

Figure Lengend Snippet: Time-fold up- or down-expression of genes analyzed by real time PCR in SSc-MVECs versus N-MVECs

Article Snippet: VIC-labeled human glyceraldehyde-3-phosphate dehydrogenase (GAPDH; #4326317E) and FAM-labeled human IL8 (#Hs00174103_m1), urokinase type plasminogen activator (PLAU; #Hs00705898_s1) KLK9 (#Hs00705898_s1), KLK11 (#Hs00170182_m1 and Hs00374668_m1), KLK12 (#Hs00377603_m1), PTX3 (#Hs00173615_m1), PLXNB1 (#Hs00182227_m1), DSG2 (#Hs00170071_m1), and connective tissue growth factor (CTGF; #Hs00170014_m1) TaqMan pre-developed assays (Applied Biosystems, Foster City, CA, USA) were used.

Techniques: Real-time Polymerase Chain Reaction

Journal: Arthritis Research & Therapy

Article Title: A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients

doi: 10.1186/ar2002

Figure Lengend Snippet: List of all the Gene Ontology significant terms with more than two annotated genes on the array (N > 2)

Article Snippet: VIC-labeled human glyceraldehyde-3-phosphate dehydrogenase (GAPDH; #4326317E) and FAM-labeled human IL8 (#Hs00174103_m1), urokinase type plasminogen activator (PLAU; #Hs00705898_s1) KLK9 (#Hs00705898_s1), KLK11 (#Hs00170182_m1 and Hs00374668_m1), KLK12 (#Hs00377603_m1), PTX3 (#Hs00173615_m1), PLXNB1 (#Hs00182227_m1), DSG2 (#Hs00170071_m1), and connective tissue growth factor (CTGF; #Hs00170014_m1) TaqMan pre-developed assays (Applied Biosystems, Foster City, CA, USA) were used.

Techniques: Chemotaxis Assay, Transduction, Coagulation

Journal: Arthritis Research & Therapy

Article Title: A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients

doi: 10.1186/ar2002

Figure Lengend Snippet: Class distribution of differentially expressed genes with a log odds ratio >1

Article Snippet: VIC-labeled human glyceraldehyde-3-phosphate dehydrogenase (GAPDH; #4326317E) and FAM-labeled human IL8 (#Hs00174103_m1), urokinase type plasminogen activator (PLAU; #Hs00705898_s1) KLK9 (#Hs00705898_s1), KLK11 (#Hs00170182_m1 and Hs00374668_m1), KLK12 (#Hs00377603_m1), PTX3 (#Hs00173615_m1), PLXNB1 (#Hs00182227_m1), DSG2 (#Hs00170071_m1), and connective tissue growth factor (CTGF; #Hs00170014_m1) TaqMan pre-developed assays (Applied Biosystems, Foster City, CA, USA) were used.

Techniques: Migration, Binding Assay, Transduction

Journal: Arthritis Research & Therapy

Article Title: A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients

doi: 10.1186/ar2002

Figure Lengend Snippet: Immunohistochemical evidence of differential expression of tissue kallikrein (KLK)9, KLK11, KLK12, and DSG2 in microvascular endothelial cells (MVECs) from normal subjects and patients with systemic sclerosis (SSc). Each panel is representative of the pattern of immune staining with each antibody obtained for the six normal and six SSc patients subjected to skin biopsies from which MVECs were prepared. The inset in the micrograph of KLK12 shows negative staining using isotype control rabbit IgG (the isotype used for KLK9 and KLK12), while that shown in the micrograph of DSG shows negative staining for mouse IgG (the isotype used for KLK11 and DSG). Original magnification, 200×.

Article Snippet: VIC-labeled human glyceraldehyde-3-phosphate dehydrogenase (GAPDH; #4326317E) and FAM-labeled human IL8 (#Hs00174103_m1), urokinase type plasminogen activator (PLAU; #Hs00705898_s1) KLK9 (#Hs00705898_s1), KLK11 (#Hs00170182_m1 and Hs00374668_m1), KLK12 (#Hs00377603_m1), PTX3 (#Hs00173615_m1), PLXNB1 (#Hs00182227_m1), DSG2 (#Hs00170071_m1), and connective tissue growth factor (CTGF; #Hs00170014_m1) TaqMan pre-developed assays (Applied Biosystems, Foster City, CA, USA) were used.

Techniques: Immunohistochemical staining, Expressing, Staining, Negative Staining

Journal: Molecules

Article Title: Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

doi: 10.3390/molecules26113105

Figure Lengend Snippet: Representative immunohistochemical staining of CCDC25 and KLK11 in human CCA tissues (magnification, ×400). ( A , B ) Negative controls; ( C ) stained CCDC25 in adjacent non-cancerous tissue of a normal bile duct; ( D ) CCDC25 in CCA tumor cells; ( E ) stained KLK11 in adjacent non-cancerous tissue of a normal bile duct; ( F ) stained KLK11 in CCA tumor cells.

Article Snippet: After that, the sections were incubated with 150 μL of anti-CCDC25 and anti-KLK11 antibody (Cat#orb2517 and orb373440, respectively, Biorbyt, Cambridge, UK) with a dilution of 1:400 and 1:150, respectively at 4 °C overnight.

Techniques: Immunohistochemical staining, Staining

Journal: Molecules

Article Title: Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

doi: 10.3390/molecules26113105

Figure Lengend Snippet: H-scores of CCDC25 and KLK11 in CCA tissues by using immunohistochemistry. ( A ) H-score of CCDC25. ( B ) H-score of KLK11. Mann–Whitney U test was used to compare H-scores between cancerous and adjacent tissues of CCDC25 and KLK11. * Statistical significance ( p < 0.05).

Article Snippet: After that, the sections were incubated with 150 μL of anti-CCDC25 and anti-KLK11 antibody (Cat#orb2517 and orb373440, respectively, Biorbyt, Cambridge, UK) with a dilution of 1:400 and 1:150, respectively at 4 °C overnight.

Techniques: Immunohistochemistry, MANN-WHITNEY

Journal: Molecules

Article Title: Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

doi: 10.3390/molecules26113105

Figure Lengend Snippet: H-score of CCDC25 and KLK11 in lymph node metastatic CCA and non-metastatic CCA. ( A ) H-score of CCDC25 in lymph node metastatic CCA. ( B ) H-score of CCDC25 in non-lymph node metastatic CCA. ( C ) H-score of KLK11 in lymph node metastatic CCA. ( D ) H-score of KLK11 in non-lymph node metastatic CCA. Mann–Whitney U test was used to compare H-score between cancerous and adjacent tissues of CCDC25 and KLK11. * Statistical significance ( p < 0.05).

Article Snippet: After that, the sections were incubated with 150 μL of anti-CCDC25 and anti-KLK11 antibody (Cat#orb2517 and orb373440, respectively, Biorbyt, Cambridge, UK) with a dilution of 1:400 and 1:150, respectively at 4 °C overnight.

Techniques: MANN-WHITNEY

Journal: Molecules

Article Title: Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

doi: 10.3390/molecules26113105

Figure Lengend Snippet: Correlation between CCDC25 and KLK11 H-score in cancerous tissues of ( A ) overall CCA patients, ( B ) CCA patients with lymph node metastasis, ( C ) CCA patients without lymph node metastasis. * Statistical significance ( p < 0.05).

Article Snippet: After that, the sections were incubated with 150 μL of anti-CCDC25 and anti-KLK11 antibody (Cat#orb2517 and orb373440, respectively, Biorbyt, Cambridge, UK) with a dilution of 1:400 and 1:150, respectively at 4 °C overnight.

Techniques:

Journal: Molecules

Article Title: Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

doi: 10.3390/molecules26113105

Figure Lengend Snippet: Kaplan–Meier survival curves of CCA patients based on H-score of CCDC25 and KLK11. CCA patients were divided into low- and high-expression using median values as cut-off for CCDC25 and KLK11 (155 and 185, respectively). The curves show overall survival of CCA patients having high expression (solid line) and low expression (dashed line). The survival times were observed between low- and high-expression groups of ( A ) CCDC25 and ( B ) KLK11 (log-rank test; p = 0.566 and p = 0.048, respectively). * Statistical significance ( p < 0.05).

Article Snippet: After that, the sections were incubated with 150 μL of anti-CCDC25 and anti-KLK11 antibody (Cat#orb2517 and orb373440, respectively, Biorbyt, Cambridge, UK) with a dilution of 1:400 and 1:150, respectively at 4 °C overnight.

Techniques: Expressing

Journal: Molecules

Article Title: Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

doi: 10.3390/molecules26113105

Figure Lengend Snippet: Expression of CCDC25 and KLK11 mRNA in CCA tissues analyzed by using GEPIA. ( A ) Expression of CCDC25 in CCA. ( B ) Expression of KLK11 in CCA. * Statistical significance ( p < 0.05).

Article Snippet: After that, the sections were incubated with 150 μL of anti-CCDC25 and anti-KLK11 antibody (Cat#orb2517 and orb373440, respectively, Biorbyt, Cambridge, UK) with a dilution of 1:400 and 1:150, respectively at 4 °C overnight.

Techniques: Expressing

Journal: Molecules

Article Title: Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

doi: 10.3390/molecules26113105

Figure Lengend Snippet: Kaplan–Meier survival curve analysis of CCDC25 and KLK11 mRNA expression levels and overall survival time of the samples obtained from GEPIA. The curves show overall survival of CCA patients having high expression (black line) and low expression (grey line). The survival time of CCA patients between low- and high-expression groups of ( A ) CCDC25 and ( B ) KLK11. * Statistical significance ( p < 0.1).

Article Snippet: After that, the sections were incubated with 150 μL of anti-CCDC25 and anti-KLK11 antibody (Cat#orb2517 and orb373440, respectively, Biorbyt, Cambridge, UK) with a dilution of 1:400 and 1:150, respectively at 4 °C overnight.

Techniques: Expressing

Journal: Molecules

Article Title: Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

doi: 10.3390/molecules26113105

Figure Lengend Snippet: The interaction map of CCDC25, KLK11, and metastasis-related proteins. Protein–ligand interaction was predicted by STRING version 11.0. Protein–protein interactions were represented by solid lines. Stronger associations were represented by thicker lines. Weak associations were represented by thin lines. CCDC25 and KLK11 were represented in solid circles. Metastasis-related proteins were represented by dashed circles.

Article Snippet: After that, the sections were incubated with 150 μL of anti-CCDC25 and anti-KLK11 antibody (Cat#orb2517 and orb373440, respectively, Biorbyt, Cambridge, UK) with a dilution of 1:400 and 1:150, respectively at 4 °C overnight.

Techniques: Protein-Protein interactions

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: The expression of KLK11 is significantly lower in ESCC tissues. A and B. Indicated detection of KLK11 expression in dataset TCGA. C and D. Indicated KLK11 protein expression in 8 pairs of ESCC tissues and their para-carcinoma tissues by western blotting. KLK11 expression in ESCC tissues were significantly lower than those in the matched adjacent non-tumor tissues. E. KLK11 protein level was measured by immunohistochemical analysis in normal tissues. F. KLK11 protein level was measured by immunohistochemical analysis in ESCC tissues. Representative images are showed at 100 × and 200 × magnifications, respectively. G. KLK11 protein level in 100 ESCC tissues and matched normal tissues. Data were representative of three independent experiments (mean and SEM). *P < 0.05.

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Expressing, Western Blot, Immunohistochemical staining

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: KLK11 expression was significantly associated with clinical characteristics

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Expressing

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: Summary of univariate and multivariate Cox regression analyses of overall survival

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Expressing

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: Low KLK11 expression was associated with poor prognosis in ESCC patients. ESCC samples from the tissue microarray were divided as two different groups, high KLK11 expression and low KLK11 expression group. Patients’ survival information was provided by the manufacture. Kaplan-Meier analysis of overall survival was done for the two group.

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Expressing, Microarray

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: The expression of KLK11 is significantly lower in ESCC cell lines. QPCR (A) and western blotting (B) showed the expression of KLK11 in seven ESCC cell lines and HEEC. KLK11 knockdown efficiency was confirmed by qPCR (C) and western blotting (D) in ESCC cells. qPCR (E) and western blotting (F) confirmed the restoration of KLK11 expression in four groups of TE-1 cells. qPCR (G) and western blotting (H) confirmed the restoration of KLK11 expression in four groups of EC18 cells. Results were showed as mean ± SD (*P < 0.05) of triplicate determination from three independent experiments.

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Expressing, Western Blot

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: KLK11 inhibited the proliferation of ESCC cells. A. KLK11 inhibited the proliferation of TE-1 cells by MTT assays. B. KLK11 inhibited the proliferation of EC18 cells by MTT assays. C. Colony formation assays showed that KLK11 overexpression inhibited TE-1 and EC18 cells proliferation. These effects were abolished by treatment with shKLK11. D. Flow cytometry analysis of cell cycle phase revealed a G0/G1 arrest induced by KLK11. Data were representative of three independent experiments (mean and SEM). *P < 0.05.

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Over Expression, Flow Cytometry

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: KLK11 affected the expression of the related factors in Wnt/β-catenin pathway and cell cycle-mediated factors. A. The expression of p-GSK-3β/GSK-3β in EC18 and TE-1 cells after lentivirus vectors delivery in each group as measured by western blot. B. The TCF/LEF luciferase ratio reported the activity of Wnt/β-catenin pathway in the indicated cells. C. Expression of CDK4, cyclin D1, CDK6, p-Rb, Rb, β-catenin (cytosol), and β-catenin (nucleus) were determined in TE-1 and EC18 cells transfected with KLK11. KLK11 inhibited the proliferation of ESCC by regulating the expression of the above proteins. D. Analysis of Ki67, cyclin D1, CDK4, CDK6, and c-myc expression in KLK11-overexpression or KLK11-knockdown ESCC cells by qPCR. Data were representative of three independent experiments (mean and SEM). *P < 0.05.

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Expressing, Western Blot, Luciferase, Activity Assay, Transfection, Over Expression

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: KLK11 down regulated the expression of Ki67 and cyclin D1 through deactivation of the Wnt/β-catenin signaling pathway. A, B. ESCC cells were pre-treated with XAV-939 for 24 h before harvesting, and the detection of Ki67, cyclin D1, c-myc, and expression levels were performed by qPCR. C, D. Treatment of EC18 and TE-1 cells with XAV-939, the expression of Ki67, cyclin D1, β-catenin (cytosol), and β-catenin (nucleus) were significantly inhibited. Data were representative of three independent experiments (mean and SEM). *P < 0.05.

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Expressing

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: KLK11 suppressed ESCC cells proliferation through inhibiting the activity of the Wnt/β-catenin pathway. A, B. XAV-939 was added to TE-1 and EC18 cells transfected with shRNA, and the proliferation of TE-1 and EC18 cells was detected by MTT assays. C. XAV-939 was added to TE-1 and EC18 cells transfected with shRNA, and the proliferation of TE-1 and EC18 cells was detected by colony formation assays. D. The relationship between KLK11 and the Wnt/β-catenin pathway. Data were representative of three independent experiments (mean and SEM). *P < 0.05.

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: Activity Assay, Transfection, shRNA

Journal: American Journal of Cancer Research

Article Title: KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma

doi:

Figure Lengend Snippet: KLK11 inhibited the proliferation of ESCC in vivo. (A, B) Tumor xenograft volume (A) and tumor size (B) in shRNA-KLK11-treated nude mice were bigger than those in the scramble group. Tumor sizes in KLK11 overexpression nude mice were smaller than those in the vector group. (C) Analysis of Ki67, cyclin D1, and KLK11 expression in mice tumor tissues with KLK11 overexpression or KLK11 knockdown by qPCR. (D) Analysis of KLK11 and Cyclin D1 in xenografts by Immunohistochemistry. Data were representative of three independent experiments (mean and SEM). *P < 0.05.

Article Snippet: Western blotting was performed according to the standard protocol with the following antibodies: anti-KLK11 antibody (Abcam, Cambridge, MA), anti-Ki67 (Abcam, Cambridge, MA), anti-GSK-3β (Abcam, Cambridge, MA), anti-Cyclin D1 antibody (Cell Signaling, Danvers, MA), anti-Rb antibody (Thermo, Waltham, MA), anti-p-Rb antibody (Bioworld Technology, Louis Park, MN, USA), anti-β-Catenin antibody (Cell Signaling, Danvers, MA), anti-CDK6 antibody (Bioworld Technology, Louis Park, MN, USA), anti-CDK4 antibody (Bioworld Technology, Louis Park, MN, USA), anti-GAPDH antibody (Bioworld Technology, Louis Park, MN, USA), anti-p84 antibody (Abcam, Cambridge, MA).

Techniques: In Vivo, shRNA, Over Expression, Plasmid Preparation, Expressing, Immunohistochemistry